Multiple Endocrine Neoplasia Type 2 (MEN 2)

Overview

Multiple Endocrine Neoplasia type 2 (MEN 2) is a rare, autosomal‑dominant hereditary syndrome that predisposes affected individuals to develop tumors in several endocrine glands. The condition is caused by germ‑line mutations in the RET proto‑oncogene. MEN 2 is divided into three clinical subtypes:

• MEN 2A – Medullary thyroid carcinoma (MTC), pheochromocytoma, and parathyroid hyperplasia.
• MEN 2B – Aggressive MTC, pheochromocytoma, mucosal neuromas, and a characteristic marfanoid habitus.
• Familial Medullary Thyroid Carcinoma (FMTC) – Isolated MTC without the other endocrine tumors.

Early identification is crucial because timely surgery (especially thyroidectomy) can be curative for MTC and can prevent life‑threatening complications from pheochromocytoma.^[1][2]

Symptoms Checklist

Because MEN 2 involves multiple organs, symptoms can vary. Use the checklist below to see which signs may be present.

• 🔹 Medullary thyroid carcinoma
  • Neck lump or nodule
  • Hoarseness or difficulty swallowing
  • Persistent cough
• 🔹 Pheochromocytoma (adrenal medulla tumor)
  • Episodes of pounding headache
  • Palpitations or rapid heart rate
  • Sweating, anxiety, or tremor
  • High blood pressure that may be episodic
• 🔹 Parathyroid hyperplasia (MEN 2A)
  • Bone pain or fractures
  • Kidney stones
  • Fatigue, weakness, or excessive thirst
• 🔹 MEN 2B specific features
  • Mucosal neuromas (bumpy growths on lips, tongue, or eyelids)
  • Marfanoid body habitus (tall, slender, long limbs)
  • Gastro‑intestinal problems (diarrhea, constipation)

Risk Factors

• Family history of MEN 2 or known RET mutation.
• First‑degree relatives (parents, siblings, children) of an affected individual.
• Ethnic groups with documented founder mutations (e.g., certain European populations).
• Early‑onset medullary thyroid carcinoma without a clear sporadic cause.

Diagnosis

Diagnosis combines clinical evaluation, biochemical testing, imaging, and genetic analysis.

1. Genetic testing – DNA sequencing of the RET gene is the gold standard. A positive result confirms the diagnosis even before tumors develop.^[3]
2. Biochemical screening
   • Serum calcitonin (elevated in MTC).
   • Plasma or urinary metanephrines and normetanephrines for pheochromocytoma.
   • Serum calcium and parathyroid hormone (PTH) for parathyroid disease.
3. Imaging studies
   • Neck ultrasound or CT to evaluate thyroid nodules.
   • CT/MRI of the adrenal glands or ^123I‑MIBG scintigraphy for pheochromocytoma.
   • Bone densitometry if hyperparathyroidism is suspected.
4. Family cascade testing – Once a pathogenic RET mutation is identified, relatives should be offered targeted genetic testing.

Treatment Options

Management is multidisciplinary, involving endocrinology, surgery, genetics, and oncology.

Medical Interventions

• Prophylactic thyroidectomy – Recommended for carriers of high‑risk RET mutations (e.g., codon 634, 918) as early as infancy to prevent MTC.^[4]
• Pheochromocytoma
  • Alpha‑adrenergic blockade (e.g., phenoxybenzamine) before any surgical removal.
  • Laparoscopic adrenalectomy is the treatment of choice.
• Parathyroid disease – Surgical removal of hyperplastic glands or medical management with calcimimetics (e.g., cinacalcet) if surgery is not feasible.
• Targeted therapy for advanced MTC – Tyrosine‑kinase inhibitors such as vandetanib or cabozantinib have FDA approval.^[5]

Home & Lifestyle Measures

• Regular blood pressure monitoring, especially if pheochromocytoma is present.
• Maintain adequate calcium and vitamin D intake if parathyroid disease is a concern.
• Stay hydrated and avoid excessive caffeine or stimulants that can provoke catecholamine surges.
• Adhere to scheduled biochemical screening (calcitonin, metanephrines) as recommended by your physician.

Prevention

Because MEN 2 is genetic, primary prevention is not possible, but risk can be dramatically reduced through:

• Genetic counseling – For families with a known RET mutation.
• Early prophylactic surgery – Removing the thyroid before malignant transformation.
• Routine surveillance – Annual biochemical tests and imaging to catch tumors at a curable stage.
• Lifestyle modifications – Controlling blood pressure, avoiding smoking, and limiting alcohol to reduce cardiovascular stress.

Living With MEN 2

• Follow a personalized surveillance schedule – Your endocrinologist will outline timing for calcitonin, metanephrines, calcium, and imaging.
• Keep a medical alert – Carry a card or bracelet noting the RET mutation and risk of pheochromocytoma, especially important for emergency care.
• Psychosocial support – Join patient advocacy groups (e.g., American Thyroid Association’s MEN 2 support network) to share experiences.
• Family planning – Discuss pre‑implantation genetic diagnosis (PGD) or prenatal testing with a genetic counselor if you plan to have children.
• Medication adherence – Take alpha‑blockers, calcimimetics, or TKIs exactly as prescribed.
• Regular exercise – Moderate activity improves cardiovascular health and helps manage stress, which can trigger catecholamine spikes.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:

• Sudden, severe headache with palpitations, sweating, or a feeling of impending doom (possible pheochromocytoma crisis).
• Chest pain, shortness of breath, or fainting.
• Rapidly rising blood pressure (e.g., >180/120 mm Hg) that does not respond to home medication.
• Severe abdominal pain with vomiting, which could indicate adrenal hemorrhage.
• Signs of hypercalcemia crisis: confusion, nausea, vomiting, or irregular heartbeat.

1. Mayo Clinic. Multiple endocrine neoplasia (MEN) – Symptoms and causes. Accessed Jan 2026.
2. National Institutes of Health (NIH) – Genetics Home Reference. Multiple endocrine neoplasia type 2. Accessed Jan 2026.
3. American Thyroid Association. MEN 2 Guidelines. 2023.
4. Cleveland Clinic. MEN 2 – Diagnosis and treatment. Updated 2024.
5. U.S. Food & Drug Administration. Vandetanib (Caprelsa) Prescribing Information. 2022.